Show simple item record

dc.contributor.authorMinchom, Aen_US
dc.contributor.authorThavasu, Pen_US
dc.contributor.authorAhmad, Zen_US
dc.contributor.authorStewart, Aen_US
dc.contributor.authorGeorgiou, Aen_US
dc.contributor.authorO'Brien, MERen_US
dc.contributor.authorPopat, Sen_US
dc.contributor.authorBhosle, Jen_US
dc.contributor.authorYap, TAen_US
dc.contributor.authorde Bono, Jen_US
dc.contributor.authorBanerji, Uen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2017-11-01T09:51:06Z
dc.date.issued2017en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28982179en_US
dc.identifierPONE-D-17-20698en_US
dc.identifier.citationPLoS One, 2017, 12 (10), pp. e0186106 - ?en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/882
dc.identifier.eissn1932-6203en_US
dc.identifier.doi10.1371/journal.pone.0186106en_US
dc.description.abstractWe investigated PD-L1 changes in response to MEK and AKT inhibitors in KRAS mutant lung adenocarcinoma (adeno-NSCLC). PD-L1 expression was quantified using immunofluorescence and co-culture with a jurkat cell-line transfected with NFAT-luciferase was used to study if changes in PD-L1 expression in cancer cell lines were functionally relevant. Five KRAS mutant cell lines with high PD-L1 expression (H441, H2291, H23, H2030 and A549) were exposed to GI50 inhibitor concentrations of a MEK inhibitor (trametinib) and an AKT inhibitor (AZD5363) for 3 weeks. Only 3/5 (H23, H2030 and A549) and 2/5 cell lines (H441 and H23) showed functionally significant increases in PD-L1 expression when exposed to trametinib or AZD5363 respectively. PD-L1 overexpression is not consistent and is unlikely to be an early mechanism of resistance to KRAS mutant adeno-NSCLC treated with MEK or AKT inhibitors.en_US
dc.format.extente0186106 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectB7-H1 Antigenen_US
dc.subjectCarcinoma, Non-Small-Cell Lungen_US
dc.subjectCell Line, Tumoren_US
dc.subjectCoculture Techniquesen_US
dc.subjectGenes, rasen_US
dc.subjectHumansen_US
dc.subjectLung Neoplasmsen_US
dc.subjectMutationen_US
dc.titleA study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-09-25en_US
rioxxterms.versionofrecord10.1371/journal.pone.0186106en_US
rioxxterms.licenseref.startdate2017en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfPLoS Oneen_US
pubs.issue10en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished onlineen_US
pubs.volume12en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Pharmacology – Adaptive Therapyen_US
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamThoracic Oncologyen_US
icr.researchteamTreatment of thoracic tumoursen_US
dc.contributor.icrauthorDe Bono, Johannen_US
dc.contributor.icrauthorBanerji, Udaien_US
dc.contributor.icrauthorO'Brien, Maryen_US
dc.contributor.icrauthorYap, Timothyen_US
dc.contributor.icrauthorPopat, Sanjayen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/